argenx SE

argenx SE

222.17
BRL
+6.29
(+2.91%)
11.52EPS
16.65P/E
313.24BMarket Cap
Feb 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.03
0.02
0.03
0.07
0.03
0.08
0.04
0.39
0.31
0.87
1.48
2.74
7.25
Basic EPS, GAAP
-0.03
-0.08
-0.04
-0.05
-0.06
-0.09
-0.19
-0.54
-0.32
-0.53
-0.21
0.56
0.85
2.34
Free Cash Flow per Basic Share
-0.03
-0.04
-0.04
0.02
-0.07
-0.07
0.11
-0.36
-0.58
-0.72
-0.33
-0.1
0.38
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.19
0.1
0.14
0.52
0.69
1.12
1.42
1.98
2.05
2.8
3.66
4.78
- -
Tangible Book Value per Share
0.11
0.19
0.1
0.14
0.52
0.69
1.07
1.28
1.85
1.93
2.71
3.54
4.6
- -
Basic Weighted Avg Shares
389
187
389
466
609
890
956
1,124
1,264
1,346
1,415
1,481
1,517
803
Sales/Revenue/Turnover
5
6
7
16
44
25
78
41
497
411
1,226
2,190
4,153
5,822
Operating Margin (%)
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
29.76
Depreciation Expense
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Net Income, GAAP
-12
-15
-17
-24
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,877
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.12
Profit Margin (%)
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
32.24
Working Capital
40
72
39
77
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
- -
LT Debt
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
- -
Total Equity
41
74
41
70
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-36.85
-26.41
-29.25
-42.67
-13.92
-14.81
-20.18
-42.63
-19.4
-26.54
-8.54
17.36
20.15
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
11
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
36
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,535
1,547
1,552
Market Capitalization
41,394
56,069
60,441

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
- -
8,068
- -
Cash, Cash Equivalents & STI
- -
5,184
- -
Accounts Receivable, Net
- -
1,832
- -
Inventories
- -
371
- -
Total Current Liabilities
- -
1,575
- -
Payables & Accruals
- -
925
- -
ST Debt
- -
11
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
91.95%
35.08%
33.19%
Free Cash Flow
-187.8%
-97.19%
-479.69%
Net Income, GAAP
23.88%
-68.95%
55.1%
Sales/Revenue/Turnover
186.88%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
1,515
1,721
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
0.49
0.06
12.94
0.56
2025
0.11
4.02
5.64
8.68
0.85
2026
0.24
7.59
0.33
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Karen Massey
Full Time Employees
1,863
Sector
Health technology
Industry
Biotechnology
Address
Laarderhoogtweg 25 Amsterdam NH Netherlands 1101 EB
IPO Date
Jul 10, 2014
Website
argenx.com
Business
argenx SE argenx SE is a commercial-stage global immunology company that develops differentiated antibody-based therapies for severe autoimmune diseases; it offers VYVGART (efgartigimod), a first-in-class FcRn blocker approved in more than 30 countries including the US, EU, UK, Japan, Israel, China and Australia for generalized myasthenia gravis (gMG) in both intravenous and subcutaneous formulations (VYVGART SC), for chronic inflammatory demyelinating polyneuropathy (CIDP) in the US, China and Japan (as VYVDURA), and for immune thrombocytopenia (ITP) in Japan (as VYVDURA); it advances empasiprubart, a C2 complement inhibitor in Phase 3 for multiple autoimmune indications including multifocal motor neuropathy; and it progresses earlier-stage candidates such as ARGX-119 (MuSK agonist) in proof-of-concept for congenital myasthenic syndrome, amyotrophic lateral sclerosis and spinal muscular atrophy, alongside preclinical assets ARGX-213 (FcRn), ARGX-121 (IgA), ARGX-220 and ARGX-109 (IL-6). The company leverages its Immunology Innovation Program (IIP) and proprietary technologies including SIMPLE ANTIBODY platform, NHANCE, ABDEG, POTELLIGENT and DHS mutations to engineer antibodies; it operates through subsidiaries in the US (Boston), Belgium (Zwijnaarde), Japan (Tokyo), France, UK, Netherlands, Switzerland, Germany, Canada, Italy, Spain, Portugal, Australia and Austria; founded in 2008 and headquartered in Amsterdam, Netherlands, argenx SE conducts R&D primarily in Belgium and commercializes products globally targeting underserved patients in immunology. Recent developments include expansion of its ENHANZE license agreement with Halozyme in September 2024 by nominating four additional targets for a total of six including FcRn and C2 to enable subcutaneous formulations; a new manufacturing partnership expansion with FUJIFILM featuring a site in North Carolina; topline results from the registrational EMPASSION Phase 3 study in multifocal motor neuropathy for empasiprubart; plans for five registrational readouts in 2026 and submission of a supplemental BLA for seronegative gMG by end-2025; and combined 2025 R&D and SG&A guidance of approximately $2.5 billion.

Company News

  • Aberdeen Group plc Sells 1,479 Shares of argenex SE $ARGX

  • NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • 3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

  • Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

  • argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

  • argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • argenx to Present at Upcoming Investor Conferences

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

  • argenx: 3 Key Takeaways for Long-Term Investors

  • 714 argenex SE $ARGX Shares Bought by Diversify Advisory Services LLC

  • argenx SE (ARGX) Q3 2026 Earnings Call Transcript

  • HRMY or ARGX: Which Is the Better Value Stock Right Now?

  • What argenex (ARGX) Said on Its Q3 Earnings Call

  • argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026